Akari Therapeutics (AKTX) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 80.1% versus a loss of 85.3%. Akari Therapeutics is the larger company by market cap ($20.0 million vs $16.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | RADX |
|---|---|---|
| Share price | $8.77 | $1.13 |
| Market cap | $20.04M | $16.49M |
| 1-day change | +3.30% | +1.80% |
| YTD return | -29.67% | -78.74% |
| 1-year return | -80.07% | -85.27% |
| 5-year return | -99.38% | — |
| EPS (TTM) | $0.00 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $16.25 |
| 52-week low | $3.02 | $1.00 |
| Distance from 52-week high | -78.08% | -93.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +190.76% | +1403.54% |
| Average volume | 61.08K | 84.72K |
| Shares outstanding | 2.29M | 14.59M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
AKTX vs RADX FAQ
Which is bigger, Akari Therapeutics or Radiopharm Theranostics?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $20.04M compared with $16.49M for Radiopharm Theranostics (RADX).
Which stock has performed better over the past year, AKTX or RADX?
AKTX returned -80.07% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.